Acquisitions - Purchase Price Allocation (Details) $ in Millions										6 Months Ended	12 Months Ended
		Mar. 01, 2016 USD ($)	Jan. 22, 2016 USD ($)		Dec. 15, 2015 USD ($)	Sep. 15, 2015 USD ($)	Aug. 28, 2015 USD ($)	May 12, 2015 USD ($)	Mar. 30, 2015 USD ($)	Dec. 31, 2015 USD ($) products	Dec. 31, 2015 USD ($) products	Apr. 02, 2016 USD ($)
Assets acquired:
Goodwill										$ 5,152.7	$ 5,152.7	$ 5,121.8
Indefinite-lived intangibles:										1,916.3	1,916.3	1,751.8
In-process research and development
Assets acquired:
Indefinite-lived intangibles:			$ 0.0	[1]						48.2	48.2	$ 69.5
Tretinoin Products
Purchase Consideration
Purchase price paid	[1]		416.4
Contingent consideration	[1]		0.0
Total purchase consideration	[1]		416.4
Assets acquired:
Inventories	[1]		1.4
Goodwill	[1]		1.7
Total intangible assets	[1]		413.3
Total assets	[1]		416.4
Tretinoin Products | Developed product technology, formulations, and product rights
Assets acquired:
Definite-lived intangibles:	[1]		411.0
Tretinoin Products | Non-compete agreements
Assets acquired:
Definite-lived intangibles:	[1]		$ 2.3
Development-Stage Rx Products
Purchase Consideration
Purchase price paid	[1]	$ 0.0
Contingent consideration	[1]	29.5
Total purchase consideration	[1]	29.5
Assets acquired:
Inventories	[1]	0.0
Goodwill	[1]	0.5
Total intangible assets	[1]	29.0
Total assets	[1]	29.5
Development-Stage Rx Products | Developed product technology, formulations, and product rights
Assets acquired:
Definite-lived intangibles:	[1]	0.0
Development-Stage Rx Products | Non-compete agreements
Assets acquired:
Definite-lived intangibles:	[1]	0.0
Development-Stage Rx Products | In-process research and development
Assets acquired:
Indefinite-lived intangibles:	[1]	$ 29.0
Entocort®
Purchase Consideration
Purchase price paid					$ 380.2
Contingent consideration					0.0
Total purchase consideration					380.2
Assets acquired:
Cash and cash equivalents					0.0
Accounts receivable					0.0
Inventories					0.2
Prepaid expenses and other current assets					0.0
Property and equipment					0.0
Goodwill					0.0
Total intangible assets					380.0
Other non-current assets					0.0
Total assets					380.2
Liabilities assumed:
Accounts payable					0.0
Short-term debt					0.0
Accrued liabilities					0.0
Payroll and related taxes					0.0
Accrued customer programs					0.0
Long-term debt					0.0
Net deferred income tax liabilities					0.0
Other non-current liabilities					0.0
Total liabilities					0.0
Net assets acquired					380.2
Entocort® | Distribution and license agreements, supply agreements
Assets acquired:
Definite-lived intangibles:					0.0
Entocort® | Developed product technology, formulations, and product rights
Assets acquired:
Definite-lived intangibles:					380.0
Entocort® | Customer relationships and distribution networks
Assets acquired:
Definite-lived intangibles:					0.0
Entocort® | Trademarks, trade names, and brands
Assets acquired:
Definite-lived intangibles:					0.0
Entocort® | Non-compete agreements
Assets acquired:
Definite-lived intangibles:					0.0
Entocort® | Trademarks, trade names, and brands
Assets acquired:
Indefinite-lived intangibles:					0.0
Entocort® | In-process research and development
Assets acquired:
Indefinite-lived intangibles:					$ 0.0
Naturwohl
Purchase Consideration
Purchase price paid						$ 150.4
Contingent consideration						0.0
Total purchase consideration						150.4
Assets acquired:
Cash and cash equivalents						4.6
Accounts receivable						3.3
Inventories						1.5
Prepaid expenses and other current assets						0.0
Property and equipment						0.0
Goodwill						61.0
Total intangible assets						111.8
Other non-current assets						0.0
Total assets						182.2
Liabilities assumed:
Accounts payable						2.8
Short-term debt						0.0
Accrued liabilities						1.6
Payroll and related taxes						0.0
Accrued customer programs						0.0
Long-term debt						0.0
Net deferred income tax liabilities						27.4
Other non-current liabilities						0.0
Total liabilities						31.8
Net assets acquired						150.4
Naturwohl | Distribution and license agreements, supply agreements
Assets acquired:
Definite-lived intangibles:						21.4
Naturwohl | Developed product technology, formulations, and product rights
Assets acquired:
Definite-lived intangibles:						0.0
Naturwohl | Customer relationships and distribution networks
Assets acquired:
Definite-lived intangibles:						25.9
Naturwohl | Trademarks, trade names, and brands
Assets acquired:
Definite-lived intangibles:						64.2
Naturwohl | Non-compete agreements
Assets acquired:
Definite-lived intangibles:						0.3
Naturwohl | Trademarks, trade names, and brands
Assets acquired:
Indefinite-lived intangibles:						0.0
Naturwohl | In-process research and development
Assets acquired:
Indefinite-lived intangibles:						$ 0.0
ScarAway®
Purchase Consideration
Purchase price paid							$ 26.7
Contingent consideration							0.0
Total purchase consideration							26.7
Assets acquired:
Cash and cash equivalents							0.0
Accounts receivable							0.0
Inventories							1.0
Prepaid expenses and other current assets							0.0
Property and equipment							0.0
Goodwill							3.5
Total intangible assets							22.2
Other non-current assets							0.0
Total assets							26.7
Liabilities assumed:
Accounts payable							0.0
Short-term debt							0.0
Accrued liabilities							0.0
Payroll and related taxes							0.0
Accrued customer programs							0.0
Long-term debt							0.0
Net deferred income tax liabilities							0.0
Other non-current liabilities							0.0
Total liabilities							0.0
Net assets acquired							26.7
ScarAway® | Distribution and license agreements, supply agreements
Assets acquired:
Definite-lived intangibles:							0.0
ScarAway® | Developed product technology, formulations, and product rights
Assets acquired:
Definite-lived intangibles:							0.5
ScarAway® | Customer relationships and distribution networks
Assets acquired:
Definite-lived intangibles:							9.8
ScarAway® | Trademarks, trade names, and brands
Assets acquired:
Definite-lived intangibles:							11.4
ScarAway® | Non-compete agreements
Assets acquired:
Definite-lived intangibles:							0.5
ScarAway® | Trademarks, trade names, and brands
Assets acquired:
Indefinite-lived intangibles:							0.0
ScarAway® | In-process research and development
Assets acquired:
Indefinite-lived intangibles:							0.0
GSK Products
Purchase Consideration
Purchase price paid							223.6
Contingent consideration							0.0
Total purchase consideration							223.6
Assets acquired:
Cash and cash equivalents							0.0
Accounts receivable							0.0
Inventories							0.0
Prepaid expenses and other current assets							0.0
Property and equipment							0.0
Goodwill							32.6
Total intangible assets							191.0
Other non-current assets							0.0
Total assets							223.6
Liabilities assumed:
Accounts payable							0.0
Short-term debt							0.0
Accrued liabilities							0.0
Payroll and related taxes							0.0
Accrued customer programs							0.0
Long-term debt							0.0
Net deferred income tax liabilities							0.0
Other non-current liabilities							0.0
Total liabilities							0.0
Net assets acquired							223.6
GSK Products | Distribution and license agreements, supply agreements
Assets acquired:
Definite-lived intangibles:							0.0
GSK Products | Developed product technology, formulations, and product rights
Assets acquired:
Definite-lived intangibles:							0.0
GSK Products | Customer relationships and distribution networks
Assets acquired:
Definite-lived intangibles:							61.5
GSK Products | Trademarks, trade names, and brands
Assets acquired:
Definite-lived intangibles:							129.5
GSK Products | Non-compete agreements
Assets acquired:
Definite-lived intangibles:							0.0
GSK Products | Trademarks, trade names, and brands
Assets acquired:
Indefinite-lived intangibles:							0.0
GSK Products | In-process research and development
Assets acquired:
Indefinite-lived intangibles:							$ 0.0
Gelcaps
Purchase Consideration
Purchase price paid								$ 37.9
Contingent consideration								0.0
Total purchase consideration								37.9
Assets acquired:
Cash and cash equivalents								4.6
Accounts receivable								7.3
Inventories								7.2
Prepaid expenses and other current assets								2.1
Property and equipment								6.0
Goodwill								6.0
Total intangible assets								11.0
Other non-current assets								0.4
Total assets								44.6
Liabilities assumed:
Accounts payable								3.3
Short-term debt								0.0
Accrued liabilities								1.6
Payroll and related taxes								0.0
Accrued customer programs								0.0
Long-term debt								0.0
Net deferred income tax liabilities								1.4
Other non-current liabilities								0.4
Total liabilities								6.7
Net assets acquired								37.9
Gelcaps | Distribution and license agreements, supply agreements
Assets acquired:
Definite-lived intangibles:								0.0
Gelcaps | Developed product technology, formulations, and product rights
Assets acquired:
Definite-lived intangibles:								0.0
Gelcaps | Customer relationships and distribution networks
Assets acquired:
Definite-lived intangibles:								6.6
Gelcaps | Trademarks, trade names, and brands
Assets acquired:
Definite-lived intangibles:								0.0
Gelcaps | Non-compete agreements
Assets acquired:
Definite-lived intangibles:								0.0
Gelcaps | Trademarks, trade names, and brands
Assets acquired:
Indefinite-lived intangibles:								4.4
Gelcaps | In-process research and development
Assets acquired:
Indefinite-lived intangibles:								$ 0.0
Restated Omega
Purchase Consideration
Purchase price paid									$ 2,983.2
Contingent consideration									0.0
Total purchase consideration									2,983.2
Assets acquired:
Cash and cash equivalents									14.7
Accounts receivable									222.9
Inventories									277.0
Prepaid expenses and other current assets									51.2
Property and equipment									130.8
Goodwill									1,688.7
Total intangible assets									3,379.0
Other non-current assets									2.4
Total assets									5,766.7
Liabilities assumed:
Accounts payable									225.0
Short-term debt									112.6
Accrued liabilities									49.3
Payroll and related taxes									51.3
Accrued customer programs									28.9
Long-term debt									1,471.0
Net deferred income tax liabilities									785.5
Other non-current liabilities									59.9
Total liabilities									2,783.5
Net assets acquired									2,983.2
Restated Omega | Distribution and license agreements, supply agreements
Assets acquired:
Definite-lived intangibles:									0.0
Restated Omega | Developed product technology, formulations, and product rights
Assets acquired:
Definite-lived intangibles:									31.4
Restated Omega | Customer relationships and distribution networks
Assets acquired:
Definite-lived intangibles:									1,056.3
Restated Omega | Trademarks, trade names, and brands
Assets acquired:
Definite-lived intangibles:									287.5
Restated Omega | Non-compete agreements
Assets acquired:
Definite-lived intangibles:									0.0
Restated Omega | Trademarks, trade names, and brands
Assets acquired:
Indefinite-lived intangibles:									2,003.8
Restated Omega | In-process research and development
Assets acquired:
Indefinite-lived intangibles:									$ 0.0
All Other
Purchase Consideration
Purchase price paid	[2]										15.3
Contingent consideration	[2]									13.9	13.9
Total purchase consideration	[2]										29.2
Assets acquired:
Cash and cash equivalents	[2]									0.0	0.0
Accounts receivable	[2]									0.0	0.0
Inventories	[2]									0.0	0.0
Prepaid expenses and other current assets	[2]									0.0	0.0
Property and equipment	[2]									0.0	0.0
Goodwill	[2]									0.0	0.0
Total intangible assets	[2]									29.2	29.2
Other non-current assets	[2]									0.0	0.0
Total assets	[2]									29.2	29.2
Liabilities assumed:
Accounts payable	[2]									0.0	0.0
Short-term debt	[2]									0.0	0.0
Accrued liabilities	[2]									0.0	0.0
Payroll and related taxes	[2]									0.0	0.0
Accrued customer programs	[2]									0.0	0.0
Long-term debt	[2]									0.0	0.0
Net deferred income tax liabilities	[2]									0.0	0.0
Other non-current liabilities	[2]									0.0	0.0
Total liabilities	[2]									0.0	0.0
Net assets acquired	[2]									$ 29.2	$ 29.2
Business acquisitions, number of products purchased | products										8	2
All Other | Distribution and license agreements, supply agreements
Assets acquired:
Definite-lived intangibles:	[2]									$ 0.0	$ 0.0
All Other | Developed product technology, formulations, and product rights
Assets acquired:
Definite-lived intangibles:	[2]									0.0	0.0
All Other | Customer relationships and distribution networks
Assets acquired:
Definite-lived intangibles:	[2]									0.0	0.0
All Other | Trademarks, trade names, and brands
Assets acquired:
Definite-lived intangibles:	[2]									0.0	0.0
All Other | Non-compete agreements
Assets acquired:
Definite-lived intangibles:	[2]									0.0	0.0
All Other | Trademarks, trade names, and brands
Assets acquired:
Indefinite-lived intangibles:	[2]									0.0	0.0
All Other | In-process research and development
Assets acquired:
Indefinite-lived intangibles:	[2]									$ 29.2	$ 29.2

[1] * Opening balance sheet is preliminary

[2] Consists of eight product acquisitions in our CHC, BCH and Rx segments.